


BACE1-IN-5

Cat. No.:	HY-130244
CAS No.:	2581114-83-0
Molecular Formula:	C ₁₈ H ₁₆ F ₅ N ₅ O ₂ S
Molecular Weight:	461.41
Target:	Beta-secretase
Pathway:	Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	BACE1-IN-5 (Compound 15) is a β -site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC ₅₀ of 9.1 nM, and also inhibits cellular amyloid- β (A β) with an IC ₅₀ of 0.82 nM. BACE1-IN-5 has a medicinal chemistry that improves hERG inhibition and P-gp efflux ^[1] .								
IC₅₀ & Target	BACE1								
In Vivo	<p>BACE1-IN-5 (Compound 15; 1-3 mg/kg; oral administration; for 2-6 hours; male ICR mice) treatment results in a significant and dose-dependent decrease of total Aβ, reduces total Aβ by 76% (4 hours) at a free brain concentration of 4.1 ng/mL (8.9 nM) at 1 mg/kg. BACE1-IN-5 demonstrates a K_{p,uu} value of 1.3 at 1 mg/kg (4 hours time point). At 3 mg/kg, a maximum Aβ reduction of 87% is achieved at a free brain concentration of 9.5 ng/mL (21 nM)^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male ICR mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>1 mg/kg, 3 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Oral administration; for 2 hours, 4 hours, and 6 hours</td> </tr> <tr> <td>Result:</td> <td>A significant and dose-dependent decrease of total Aβ was seen, reduced total Aβ by 76% (4 h) at a free brain concentration of 4.1 ng/mL (8.9 nM) at 1 mg/kg. Demonstrates a K_{p,uu} value close to 1 (K_{p,uu} of 1.3) at 1 mg/kg (4 h time point). At 3 mg/kg, a maximum Aβ reduction of 87% was achieved at a free brain concentration of 9.5 ng/mL (21 nM).</td> </tr> </table>	Animal Model:	Male ICR mice ^[1]	Dosage:	1 mg/kg, 3 mg/kg	Administration:	Oral administration; for 2 hours, 4 hours, and 6 hours	Result:	A significant and dose-dependent decrease of total A β was seen, reduced total A β by 76% (4 h) at a free brain concentration of 4.1 ng/mL (8.9 nM) at 1 mg/kg. Demonstrates a K _{p,uu} value close to 1 (K _{p,uu} of 1.3) at 1 mg/kg (4 h time point). At 3 mg/kg, a maximum A β reduction of 87% was achieved at a free brain concentration of 9.5 ng/mL (21 nM).
Animal Model:	Male ICR mice ^[1]								
Dosage:	1 mg/kg, 3 mg/kg								
Administration:	Oral administration; for 2 hours, 4 hours, and 6 hours								
Result:	A significant and dose-dependent decrease of total A β was seen, reduced total A β by 76% (4 h) at a free brain concentration of 4.1 ng/mL (8.9 nM) at 1 mg/kg. Demonstrates a K _{p,uu} value close to 1 (K _{p,uu} of 1.3) at 1 mg/kg (4 h time point). At 3 mg/kg, a maximum A β reduction of 87% was achieved at a free brain concentration of 9.5 ng/mL (21 nM).								

REFERENCES

[1]. Kusakabe KI, et al. Trifluoromethyl Dihydrothiazine-Based β -Secretase (BACE1) Inhibitors with Robust Central A β Reduction and Minimal Covalent Binding Burden. ChemMedChem. 2019 Oct 27.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA